Saturday 17 October 2026
Export IMCR’s income statement to Excel — free account
Immunocore Holdings PLC Sponsored ADR
IMCR Healthcare Biotechnology
Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024. In the quarter to June 2026, revenue grew 18.3%, EPS grew 92.1%, free cash flow fell 40.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years.
29.40
0.08
−0.27%
Follow IMCR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 6 | 5 | 3 | 4 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
4.37 | 4.75 | 14.04 | 14.53 | 39.89 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
1.52 | 1.19 | 7.91 | 7.36 | 2.05 | — | — | — | — |
P/FCF ratio |
0.00 | 70.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
2.37 | 2.21 | 1.24 | 1.62 | (2.45) | (5.05) | (7.69) | (5.27) | — |
P/Operating CF |
(53.51) | (105.71) | (197.51) | (218.22) | (65.67) | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
(2.40) | (3.03) | (2.38) | 0.32 | (3.14) | (1.83) | — | — | — |
P/B ratio |
4.59 | 4.09 | 9.50 | 7.48 | 6.17 | 0.00 | 0.00 | 0.00 | — |
Price to Tangible BV |
4.61 | 4.11 | 9.55 | 7.49 | 6.17 | 0.00 | 0.00 | 0.00 | — |
EV/Sales |
3.31 | 3.53 | 12.46 | 12.51 | 33.33 | 0.00 | 0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(123.66) | 41.96 | 1,057.51 | (44.32) | (9.20) | 0.00 | 0.00 | 0.00 | — |
EV/FCF |
(88.01) | 52.24 | (1,251.14) | (42.42) | (9.11) | 0.00 | 0.00 | 0.00 | — |
Quick Ratio |
3.81 | 4.16 | 3.56 | 4.32 | 4.29 | 2.78 | 1.47 | 3.44 | — |
Current Ratio |
4.04 | 4.38 | 3.80 | 4.70 | 4.29 | 2.78 | 1.47 | 3.45 | — |
Net Debt/EBITDA |
11.19 | 6.48 | 7.10 | 7.65 | 1.37 | 0.88 | 0.15 | 1.14 | — |
Debt/Assets |
36.83% | 38.73% | 8.04% | 9.08% | 20.74% | 31.36% | 30.95% | 9.64% | 0.00% |
Debt/Equity |
1.03 | 1.08 | 0.13 | 0.14 | 0.36 | 1.12 | 3.89 | 0.33 | — |
Asset Turnover |
0.39 | 0.39 | 0.44 | 0.37 | 0.11 | 0.16 | 0.13 | 0.25 | — |
Operating CF/Net income |
0.30 | (0.51) | (0.05) | 0.94 | 0.73 | 0.82 | 0.98 | 0.23 | — |
Capex/Depreciation |
(1.33) | (1.22) | (1.33) | (0.51) | (0.13) | (0.27) | (0.46) | 0.00 | — |
Interest Coverage |
(3.73) | (3.74) | (11.57) | (9.56) | (23.25) | (25.54) | (12.62) | (114.60) | — |
| (9.58%) | (14.00%) | (15.62%) | (18.28%) | (117.84%) | (211.59%) | (291.91%) | (208.47%) | — | |
| (3.42%) | (6.36%) | (9.84%) | (11.16%) | (54.14%) | (38.81%) | (54.57%) | (76.61%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(4.66%) | (7.02%) | (13.86%) | (13.79%) | (62.48%) | (66.34%) | (109.81%) | (52.65%) | — |
Average Days of Receivables |
69.16 | 74.14 | 76.23 | 70.30 | 341.88 | 281.38 | 711.67 | 679.12 | — |
Research and Development Expense of Revenue |
68.71% | 71.61% | 65.57% | 58.45% | 276.12% | 248.42% | 389.54% | 354.33% | — |
Selling, General and Administrative Expense of Revenue |
41.35% | 50.22% | 57.93% | 70.58% | 333.33% | 151.89% | 172.13% | 120.42% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
9.42% | 11.02% | 13.02% | 18.86% | 135.22% | 27.10% | 11.91% | 0.00% | — |
Graham Net Nets |
0.18 | 0.19 | 0.09 | 0.11 | 0.13 | 0.00 | 0.00 | 0.00 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(2.03%) | (3.46%) | (1.65%) | (2.04%) | (12.41%) | (3.63%) | (3.63%) | (3.63%) | — |
Free Cash Flow Yield |
(0.86%) | 1.42% | (0.07%) | (2.03%) | (9.17%) | 0.00% | 0.00% | 0.00% | — |
Revenue per Share |
7.95 | 6.21 | 5.10 | 3.81 | 0.86 | 1.46 | 7.35 | 0.00 | — |
Operating CF per Share |
(0.21) | 0.52 | 0.06 | (1.08) | (3.11) | (2.93) | (29.03) | 0.00 | — |
Capex per Share |
(0.09) | (0.10) | (0.11) | (0.06) | (0.03) | (0.12) | (1.20) | 0.00 | — |
Free Cash Flow per Share |
(0.30) | 0.42 | (0.05) | (1.14) | (3.14) | (3.05) | (30.23) | 0.00 | — |
Cash per Share |
17.16 | 16.41 | 9.05 | 8.80 | 7.70 | 6.28 | 21.25 | 0.00 | — |
Shareholders Equity per Share |
7.57 | 7.22 | 7.54 | 7.41 | 5.55 | 2.68 | 4.23 | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
7.57 | 7.22 | 7.54 | 7.41 | 5.55 | 2.68 | 4.23 | 0.00 | — |
Free Cash Flow |
(15.05) | 20.93 | (2.48) | (51.91) | (133.44) | (80.86) | (134.80) | (22.17) | — |
Working Capital |
750.05 | 717.68 | 389.80 | 373.14 | 277.15 | 125.75 | 50.78 | 154.84 | — |
Capital Expenditures |
(4.34) | (5.13) | (5.42) | (2.70) | (1.28) | (3.08) | (5.36) | (4.72) | — |
Net Current Asset Value |
310.51 | 281.07 | 300.66 | 286.12 | 182.20 | 14.23 | (59.50) | 40.74 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.02 | 0.04 | 0.08 | 0.16 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.28 | 0.42 | 0.44 | 0.68 | 0.78 | 0.65 | 0.17 | 0.34 | — |
Cash ROIC |
(0.92%) | 1.33% | (0.29%) | (6.58%) | (20.56%) | (25.50%) | (72.08%) | (8.71%) | — |
Accounts Receivable Turnover |
5.76 | 5.39 | 5.82 | 5.15 | 1.14 | 0.83 | 0.53 | 0.50 | — |
Accounts Payable Turnover |
0.21 | 0.13 | 0.06 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
0.83 | 0.55 | 0.40 | 0.00 | — | — | — | — | — |
Average Days of Payables |
1,748.15 | 3,354.63 | 6,264.48 | 4,843.20 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
483.75 | 727.86 | 1,584.25 | 231.94 | — | — | — | — | — |
Average Receivables |
69.40 | 57.55 | 42.84 | 33.87 | 31.98 | 46.86 | 61.30 | 62.49 | — |
Average Payables |
24.73 | 21.45 | 16.12 | 31.59 | 40.88 | 35.35 | 22.94 | 14.52 | — |
Average Inventory |
6.09 | 4.97 | 2.60 | — | — | — | — | — | — |
Average Assets |
1,038.39 | 803.25 | 561.88 | 470.87 | 334.08 | 245.13 | 243.20 | 124.67 | — |
Average Common Equity |
370.87 | 364.78 | 353.87 | 287.40 | 153.48 | 44.96 | 45.46 | 45.82 | — |
Columns are period end dates